Get the Stockscreener App
243.34
3.20%
-8.04
Praxis Precision Medicines Inc stock is traded at $243.34, with a volume of 622.17K.
It is down -3.20% in the last 24 hours and down -26.38% over the past month.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
See More
Previous Close:
$251.38
Open:
$250.09
24h Volume:
622.17K
Relative Volume:
1.23
Market Cap:
$6.79B
Revenue:
$7.46M
Net Income/Loss:
$-326.53M
P/E Ratio:
-18.19
EPS:
-13.3803
Net Cash Flow:
$-282.53M
1W Performance:
-12.47%
1M Performance:
-26.38%
6M Performance:
-29.18%
1Y Performance:
+363.33%
1-Day Range:
$0.00
$0.00
1-Week Range:
$241.53
$273.96
52-Week Range:
$50.56
$392.70
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Name
Praxis Precision Medicines Inc
Sector
Industry
Phone
617-300-8460
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
243.34 | 6.79B | 7.46M | -326.53M | -282.53M | -13.38 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-13-26 | Initiated | Goldman | Buy |
| Jun-18-26 | Initiated | RBC Capital Mkts | Outperform |
| Apr-10-26 | Initiated | Raymond James | Strong Buy |
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Feb-02-26 | Initiated | Wells Fargo | Equal Weight |
| Dec-15-25 | Reiterated | Oppenheimer | Outperform |
| Nov-19-25 | Initiated | BTIG Research | Buy |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-03-25 | Reiterated | H.C. Wainwright | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Aug-05-24 | Initiated | Oppenheimer | Outperform |
| Jun-24-24 | Initiated | Needham | Buy |
| Jun-18-24 | Initiated | Guggenheim | Buy |
| May-01-24 | Initiated | Robert W. Baird | Outperform |
| Sep-19-23 | Initiated | Truist | Buy |
| Jun-06-22 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Aug-26-21 | Initiated | BofA Securities | Buy |
| Apr-26-21 | Initiated | William Blair | Outperform |
| Nov-11-20 | Initiated | Wedbush | Outperform |
| Nov-10-20 | Initiated | Cowen | Outperform |
| Nov-10-20 | Initiated | Evercore ISI | Outperform |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Praxis Precision Medicines Inc Stock (PRAX) Latest News
Praxis and Remagine partner to develop ulixacaltamide patch - scanx.trade
Praxis grants 951 RSUs to new employees under inducement plan - scanx.trade
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance UK
Fourteen new employees receive Praxis stock awards covering 3,478 shares. - Stock Titan
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Praxis Precision Medicines: Still Potential Upside After Huge Rally (Rating Upgrade) - Seeking Alpha
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
(PRAX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Sixty-six new employees receive stock awards from Praxis. They vest over four years. - Stock Titan
Praxis Precision Medicines (PRAX) Climbs 1.23% as Shares Press Toward $375.69 ResistanceRounding Top - careplusvn.com
PRAX Stock Price, Quote & News - Syfe
S&P 500 Futures Drop in Premarket Trading; Praxis Precision Meds, Science Applications Lead - Barron's
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities - Yahoo Finance
Breakeven On The Horizon For Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Moomoo
PRAX Maintains by Goldman Sachs -- Price Target Raised to $575 - GuruFocus
Praxis Precision Medicines Slides as Investors Appear to Lock In Gains After Recent Rally - Quiver Quantitative
Goldman Sachs Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $575 - Moomoo
Praxis (PRAX) Update: Climbs 1.92% to $376.94 for the Current Session; the Supplied Trading Band Runs From $358.09 to $395.79Percent Below MA - vinanet.vn
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock - Yahoo Finance
Praxis Precision Medicine Number of Employees 2026 | Employee Count & Headcount Data - reveliolabs.com
Oppenheimer Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $650 - Moomoo
Praxis Precision Medicines (NASDAQ:PRAX) Hits New 1-Year HighWhat's Next? - MarketBeat
Praxis Precision Medicines (NASDAQ:PRAX) Trading 6.3% HigherStill a Buy? - MarketBeat
Praxis Precision Medicines stock hits 52-week high at 388.27 USD - Investing.com Nigeria
Praxis Precision Medicines stock hits 52-week high at 388.27 USD - Investing.com
Praxis Precision Medicines stock hits 52-week high at 388.27 USD - Investing.com Canada
Praxis Precision Medicines Could Be Approaching 'Perfect Trifecta,' Oppenheimer Says - marketscreener.com
Raymond James Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Announces Target Price $945 - Moomoo
Raymond James raises Praxis Precision Medicines price target on pipeline outlook By Investing.com - Investing.com Australia
Raymond James raises Praxis Precision Medicines price target on pipeline outlook - Investing.com Australia
Raymond James raises Praxis Precision Medicines price target on pipeline outlook - Investing.com India
Raymond James raises Praxis Precision Medicines price target on pipeline outlook - Investing.com
Praxis Precision Medicines (PRAX) Holds Near $366.81 as Consolidation Tightens Between Key LevelsBlock Trade Flow - vinanet.vn
9,840 Shares in Praxis Precision Medicines, Inc. $PRAX Purchased by Handelsbanken Fonder AB - MarketBeat
Praxis Precision Medicines (PRAX): Orbis, Allan Gray disclose 5.5% ownership stake - Stock Titan
(PRAX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Praxis (PRAX) Q2 2026 Earnings Call Transcript - AOL.com
Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 12-Month HighHere's Why - MarketBeat
PRAX Stock Drops 12% After Hours On Trial Setback — Retail Eyes FDA Approval Of Other Pipeline Candidates - Stocktwits
Praxis Precision Medicines (PRAX) Edges Higher as Biotech Momentum Holds Above Key SupportQuality Factor - dars.gov.et
4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year - TradingView
Equities Analysts Offer Predictions for PRAX Q3 Earnings - MarketBeat
Praxis Precision Medicines (PRAX) Edges Higher as Biotech Momentum Holds Above Key SupportWeak Sell Signals - vinanet.vn
H.C. Wainwright Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,201 - Moomoo
Weekly Recap: Cash runway into 2028 and RBC raises price target - TradingView
High Growth Tech Stocks in the US to Watch - simplywall.st
Dimensional Fund Advisors LP Has $10.04 Million Holdings in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines Inc Stock (PRAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Praxis Precision Medicines Inc Stock (PRAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DeSimone Jill | Director |
Jun 24 '26 |
Sale |
311.32 |
11,600 |
3,611,335 |
2,337 |
| DeSimone Jill | Director |
Jun 24 '26 |
Proposed Sale |
311.32 |
11,600 |
3,611,336 |
0 |
| Nemiroff Alex | General Counsel and Secretary |
Nov 20 '25 |
Option Exercise |
73.76 |
25,130 |
1,853,531 |
45,962 |
| Nemiroff Alex | General Counsel and Secretary |
Nov 20 '25 |
Sale |
193.09 |
25,130 |
4,852,256 |
20,832 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Option Exercise |
61.12 |
13,600 |
831,257 |
24,042 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Sale |
192.08 |
13,600 |
2,612,244 |
10,442 |
| Nemiroff Alex | Officer |
Nov 20 '25 |
Proposed Sale |
193.09 |
25,130 |
4,852,249 |
0 |
| Mastrocola Lauren | Officer |
Nov 20 '25 |
Proposed Sale |
192.08 |
13,600 |
2,612,239 |
0 |
| MITCHELL DEAN J | Director |
Option Exercise |
39.51 |
12,251 |
483,991 |
17,251 |
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):